Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morality gene

- PMLiVE

GSK discontinues two feladilimab trials in head and neck cancer

Decision made after recommendation from Independent Data Monitoring Committee

- PMLiVE

GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

Vaccine candidate is expected to be submitted to UK regulatory authorities in Q2

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

GSK and Medicago initiate late-stage COVID-19 vaccine study

Plant-based, adjuvanted vaccine candidate received FDA fast track designation in February

- PMLiVE

Edging towards success

Evolution tells us to look for small advantages, not big leaps

- PMLiVE

GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients

- PMLiVE

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study

Move comes after recommendation from independent data and safety monitoring board

- PMLiVE

Back to the future

Five years ago, an influential book used Darwin’s ideas to predict the future of the industry – how did that work out?

- PMLiVE

GSK launches late-stage testing of RSV vaccine candidate in older adults

Vaccine candidate was found to be well-tolerated in a phase 1/2 trial

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links